// App-Quantinova.ai

4505 : Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).

Researchers

Presenter

  • Srikala S. Sridhar

Principal Investigators

  • Ben Tran

  • M. Neil Reaume

  • Scott A. North

  • Martin R. Stockler

  • Kim N. Chi

  • Neil Eric Fleshner

  • Geoffrey Liu

  • John W Robinson

  • Som Mukherjee

  • Yasmin Rahim

  • Eric Winquist

  • Christopher M. Booth

  • Nghia Trung Nguyen

  • Emma Kate Beardsley

  • Nimira S. Alimohamed

  • Gail T McDonald

  • Keyue Ding

  • Wendy R. Parulekar

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Australia, Victoria, Australia

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Juravinski Cancer Centre, Burlington, ON, Canada

  • Stronach Regional Cancer Centre, Newmarket, ON, Canada

  • Western University and London Health Sciences Centre, London, ON, CA

  • Queen's University, Kingston, ON, CA

  • Hosp Charles-LeMoyne, Montreal, QC, Canada

  • Frankston Hospital/Cabrini/Monash University, Parkdale, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, ON, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

Locations

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Paclitaxel

  • taxane

Outcome

  • N/A


Study Design

  • Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02033993

Sponsors

  • N/A

Result

  • Final